利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.008 秒)

    HAEMOPOIETIC GROWTH FACTOR ANTAGONISTS
    1.
    发明公开
    HAEMOPOIETIC GROWTH FACTOR ANTAGONISTS 失效
    的粒细胞 - 巨噬细胞集落刺激因子的拮抗剂（GM-CSF）

    公开(公告)号：EP0715633A1

    公开(公告)日：1996-06-12

    申请号：EP94922181.0

    申请日：1994-07-28

    申请人： MEDVET SCIENCE PTY. LTD.

    发明人： VADAS, Mathew Alexander ,  LOPEZ, Angel Francisco ,  SHANNON, Mary Frances

    IPC分类号： C12N15 ,  A61K38 ,  A61P7 ,  C07K14 ,  C12N1 ,  C12P21 ,  C12R1

    CPC分类号： C07K14/505 ,  A61K38/00 ,  C07K14/535 ,  C07K14/54

    摘要： The present invention relates to modified and variant forms of haemopoietic growth factors (HGF) capable of acting as antagonists to the corresponding native haemopoietic growth factors and their use in ameliorating aberrant effects caused by the native molecules. A modified haemopoietic growth factor (HGF) is characterized by being in unglycosylated form and comprising a sequence of amino acids within a first α-helix wherein one or more exposed amino acids in said first α-helix having acidic or acidic-like properties are substituted with a basic amino acid residue. The preferred HGF are granulocyte-macrophage colony-stimulating factor (GM-CSF), interleuking (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, G-CSF and erythropoietin (EPO).

    SCREENING METHOD
    2.
    发明公开
    SCREENING METHOD 审中-公开
    筛选方法

    公开(公告)号：EP2758778A1

    公开(公告)日：2014-07-30

    申请号：EP12833527.0

    申请日：2012-09-21

    申请人： Medvet Science Pty Ltd

    发明人： SCHWARZ, Quenten Philip ,  LOPEZ, Angel Francisco

    IPC分类号： G01N33/50 ,  G01N33/68 ,  C12N15/12

    CPC分类号： C12Q1/6883 ,  C07K14/4705 ,  G01N33/5088 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2333/4706 ,  G01N2500/00 ,  G01N2800/30 ,  G01N2800/302 ,  G01N2800/50 ,  G01N2800/52

    摘要： The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 1 4-3-3ζ. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3 ζ. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient. The method of the present invention is useful in a wide range of applications including, inter alia, providing a means of identifying mammals susceptible to the onset of a neuropsychiatric condition, such as a condition characterized by one or more symptoms of schizophrenia, thereby enabling the implementation of prophylactic or early therapeutic intervention in an effort to either minimize or prevent the onset of the condition. It also provides a means of confirming diagnoses which would otherwise be based solely on an assessment of positive and negative symptoms.

    摘要翻译： 本发明提供了筛选哺乳动物神经精神障碍发作或易患发病的方法。 更具体地说，本发明提供了通过筛选蛋白14-3-3ζ的功能水平降低来筛选哺乳动物发病或易患精神分裂症的方法。 在相关方面，本发明还提供了通过筛选蛋白质14-3-3ζ的功能水平的变化来监测被诊断患有神经精神病症例如精神分裂症的患者的手段。 例如，在评估预防性或治疗性治疗方案的有效性或另外监测患者中可能发生的生理或代谢变化的影响的情况下，这可能是有用的。 本发明的方法可用于广泛的应用，尤其包括提供鉴定易受神经精神病症状发作影响的哺乳动物（例如以精神分裂症的一种或多种症状为特征的病症）的手段， 实施预防性或早期治疗性干预以尽量减少或预防病症的发作。 它还提供了确认诊断的手段，否则这些诊断将仅基于评估正面和负面症状。